[Editorial] Rethinking recruitment to clinical trials in Alzheimer's disease

Author profile image Aggregator
0 comments
Since the first regulatory approval of an anti-amyloid therapy in 2021, the number of clinical trials in Alzheimer's disease and of agents tested has continued to increase. According to the annual review of the Alzheimer's disease drug development pipeline, 158 agents were being tested in 192 phase 1โ€“3 clinical trials in January 2026. The World Alzheimer Report 2026, A New Era in Dementia Clinical Trials, published by Alzheimer's Disease International in September, welcomes the vitality of this pipeline but warns that recruitment must improve for its promise to be fulfilled.

Source: The Lancet Neurology - Current Issue Published 30 Nov 2026 Imported 19 Nov 2026 Relevancy: Not reviewed

Read the article